BOLD News and Press, Boundless Bio Inc.

2026-05-08 07:35:09 ET More on Boundless Bio Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader Seeking Alpha’s Quant Rating on Boundless Bio Historical earnings data for Boundless Bio Financial information f...

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company int...

2026-05-07 18:50:04 ET Boundless Bio, Inc. (BOLD) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.93%. The average open to low on the day of earnings was -4.56%. The average open to cl...

2026-05-07 18:45:06 ET Boundless Bio, Inc. (BOLD) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in BOLD stock price following earnings has averaged ±2.72% , with a median of 1.72%. ...

SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical data supp...

2026-03-20 03:25:29 ET Thesis overview Boundless Bio ( BOLD ) is a biotech aiming to develop treatments for oncology indications by targeting ecDNA (extrachromosomal DNA)-dependent tumors. Currently, their lead (and only clinical-stage) asset is BBI-940, which aims to eliminate ...

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming po...

Boundless Bio Inc. (BOLD) is expected to report $-0.44 for Q4 2025

2026-03-09 07:06:17 ET More on Boundless Bio Seeking Alpha’s Quant Rating on Boundless Bio Historical earnings data for Boundless Bio Financial information for Boundless Bio Read the full article on Seeking Alpha For further details see: Bo...

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD) , a clini...